Treated Site Characteristics (n = 40 Sites)
| Characteristic | Prostate/prostate bed (n = 5) | Lymph nodes (n = 15) | Bones (n = 19) | Viscera (n = 1) |
|---|---|---|---|---|
| Median size (cm) | 3.8 (IQR: 2.9–4.0) | 1.1 (IQR: 0.6–1.1) | 1.6 (IQR: 1.2–2.2) | 2.0 |
| Median SUVmax | 10.4 (IQR: 4.2–30.2) | 12.6 (IQR: 6.7–28.7) | 7.8 (IQR: 3.7–14.5) | 17.8 |
| Location | ||||
| Prostate | 3 (60.0%) | |||
| Prostate bed | 1 (20.0%) | |||
| Bladder base | 1 (20.0%) | |||
| Pelvic lymph nodes | 9 (60.0%) | |||
| Retroperitoneal lymph nodes | 6 (40.0%) | |||
| Pelvic bone | 8 (42.1%) | |||
| Spine | 6 (31.6%) | |||
| Ribs/sternum | 4 (21.1%) | |||
| Skull | 1 (5.3%) | |||
| Corpus cavernosum | 1 (100%) | |||
| Treatment modality | ||||
| SBRT | 3 (60.0%) | 8 (53.3%) | 19 (100%) | 0 (0.0%) |
| Intensity-modulated radiotherapy | 2 (40.0%) | 7 (46.7%) | 0 (0.0%) | 0 (0.0%) |
| High-dose-rate brachytherapy | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100%) |
| Dose and fractionation | ||||
| 35–40 Gy in 5 fractions | 3 (60.0%) | |||
| 66–74 Gy in 37 fractions | 2 (40.0%) | |||
| 32 Gy in 4 fractions | 1 (6.7%) | |||
| 30–40 Gy in 5 fractions | 7 (46.7%) | |||
| 55–60 Gy in 23–33 fractions | 4 (26.7%) | |||
| Unknown | 3 (20%) | |||
| 18 Gy in 1 fraction | 2 (10.5%) | |||
| 18–27 Gy in 3 fractions | 10 (52.6%) | |||
| 25 Gy in 5 fractions | 1 (5.3%) | |||
| 35–50 Gy in 5 fractions | 6 (31.6%) | |||
| 35 Gy in 8 fractions | 1 (100%) |